DFTX vs ERAS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DFTX · Definium Therapeutics$33.27 ▲ 9.59%
ERAS · Erasca$14.41 ▲ 8.59%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DFTX +183.1%
- ERAS +529.3%
Head to head
| Metric | DFTX | ERAS |
|---|---|---|
| Price | $33.27 | $14.41 |
| Change today | ▲ 9.59% | ▲ 8.59% |
| Market cap | $4.47B | $5.04B |
| Return, 3 months | -26.3% | -20.5% |
| Return, year to date | +148.5% | +287.4% |
| Return, 1 year | +184.4% | +534.8% |
| P/E (TTM) | – | – |
| P/B | 4.9 | 13.9 |
| P/E percentile vs own 5y | 10th | 13th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -271.9% | -30.1% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -64.1% | -78.2% |
| Analyst target vs. price | +122.6% | +67.5% |
| Analyst buy share | 100% | 71% |
| RSI (14) | 44 | 48 |
| 30-day volatility | 69.6% | 72.2% |
| Max drawdown, 1 year | -37.3% | -59.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ERAS is the largest of the group by market value.
- ERAS has returned the most over the past year.
- DFTX has been the calmest stock over the last 30 days.